Compare · MMM vs VVOS
MMM vs VVOS
Side-by-side comparison of 3M Company (MMM) and Vivos Therapeutics Inc. (VVOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and VVOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $80.24B, about 6638.1x VVOS ($12.1M).
- Over the past year, MMM is up 9.1% and VVOS is down 63.8% - MMM leads by 72.9 points.
- VVOS has been more active in the news (5 items in the past 4 weeks vs 4 for MMM).
- MMM has more recent analyst coverage (25 ratings vs 1 for VVOS).
- Company
- 3M Company
- Vivos Therapeutics Inc.
- Price
- $157.32+2.23%
- $0.77-11.58%
- Market cap
- $80.24B
- $12.1M
- 1M return
- +9.81%
- +15.25%
- 1Y return
- +9.10%
- -63.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 1
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Latest MMM
- 3M Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- 3M Announces New Board Appointment
- SEC Form SD filed by 3M Company
- 3M Announces Upcoming Investor Event
- 3M Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Sweet Thomas W was granted 1,360 shares (SEC Form 4)
- Director Kereere Suzan was granted 1,360 shares, increasing direct ownership by 27% to 6,422 units (SEC Form 4)
- Director Fitterling James R was granted 1,360 shares (SEC Form 4)
- Director Brown Thomas K was granted 1,360 shares (SEC Form 4)
- Director Chow Anne H was granted 1,360 shares (SEC Form 4)
Latest VVOS
- Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure
- Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
- SEC Form 10-Q filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
- SEC Form NT 10-Q filed by Vivos Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Vivos Therapeutics Inc.
- SEC Form EFFECT filed by Vivos Therapeutics Inc.
- SEC Form 424B3 filed by Vivos Therapeutics Inc.
- Amendment: SEC Form S-3/A filed by Vivos Therapeutics Inc.